- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-278/22 R: Order of the President of the General Court of 4 August 2022 — Biogen Netherlands v Commission (Interim relief — Medicinal products for human use — Regulation (EC) No 726/2004 — Marketing authorisation for Dimethyl fumarate Neuraxpharm — dimethyl fumarate — Application for suspension of operation of a measure — No urgency)
ECLI:EU:UNKNOWN:62022TB0278
62022TB0278
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
17.10.2022
Official Journal of the European Union
C 398/27
(Case T-278/22 R)
(Interim relief - Medicinal products for human use - Regulation (EC) No 726/2004 - Marketing authorisation for Dimethyl fumarate Neuraxpharm - dimethyl fumarate - Application for suspension of operation of a measure - No urgency)
(2022/C 398/32)
Language of the case: English
Parties
Applicant: Biogen Netherlands BV (Badhoevedorp, Netherlands) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission (represented by: L. Haasbeek and A. Sipos, acting as Agents)
Re:
By its application based on Articles 278 and 279 TFEU, the applicant seeks suspension of the operation of Commission Implementing Decision C(2022) 3254 final of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘Dimethyl fumarate Neuraxpharm — dimethyl fumarate’ as a medicinal product for human use.
Operative part of the order
1.The application for interim measures is dismissed.
2.The costs are reserved.